Avidity as a marker of protection against hepatitis E during a genotype 1 outbreak in South Sudan
In a genotype 1 hepatitis E outbreak in South Sudan, IgG avidity testing revealed that prior natural immunity is strongly protective against disease, with the majority of cases occurring in previously uninfected individuals and reinfections being rare and less likely to result in viremia.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
In many parts of the world where clean water is scarce, a virus called hepatitis E circulates constantly, infecting people who drink from contaminated sources. When this virus strikes, it causes the liver to swell and fail, leading to a condition known as acute hepatitis. For most people, the illness is severe but temporary, yet for pregnant women, it can be fatal. Scientists have long known that once a person recovers from this infection, their body builds up antibodies, which are protective proteins that remember the virus. However, in places where the virus is everywhere, almost everyone eventually carries these antibodies, making it difficult to tell who is truly safe from getting sick again and who is just carrying the memory of a past infection. The antibodies themselves do not stay the same forever; immediately after an infection, they are weak and loose in their grip, but over many months, they tighten and become much stronger, a process that scientists call maturation. Understanding whether this maturation offers real protection against a new infection is crucial for planning how to stop outbreaks, but standard tests cannot distinguish between the fresh, weak antibodies of a new infection and the old, strong ones of a past one.
Researchers in South Sudan faced this exact puzzle during a major outbreak of the virus in a crowded displaced persons camp. The virus there is a specific type, known as genotype one, which is common in Africa and Asia. To solve the mystery of who was protected, a team of scientists traveled to the camp to study hundreds of people who had fallen ill with symptoms of hepatitis. Instead of just checking for the presence of antibodies, they looked at how tightly those antibodies held onto the virus. They used a special laboratory technique that could separate the weak, fresh antibodies from the strong, mature ones. By doing this, they could tell the difference between someone who was getting sick for the first time and someone who was getting sick again despite having a history of infection.
The study began by enrolling over a thousand people who had come to the camp hospital with yellowing skin and other signs of liver trouble. The team tested their blood to confirm who actually had the virus and who did not. Among those who were confirmed to be sick, the researchers measured the strength of their antibody grip. They found a striking pattern: the vast majority of people who were sick had weak, immature antibodies, indicating they were encountering the virus for the first time. In contrast, the people who were sick but had strong, mature antibodies were very rare. This suggested that having a previous infection and the resulting strong antibodies made a person highly unlikely to get sick again. When the researchers compared the sick people to those who were sick but did not have the virus, they calculated that having this mature immunity reduced the odds of getting the disease by about ninety-five percent.
The scientists also looked at what happened inside the bodies of the few people who did get sick despite having strong, mature antibodies. They found that these individuals were much less likely to have the virus actively multiplying in their blood compared to those with weak antibodies. This indicated that the strong antibodies were acting like a shield, stopping the virus from taking hold and spreading through the body. For the small number of people whose immune systems did not stop the virus completely, the damage to the liver was no different than it was for anyone else, suggesting that the protection works by preventing the infection from starting rather than by making the illness milder once it has begun.
This work provides a clear picture of how natural immunity works against this specific virus in a real-world setting. It shows that in a place where the virus is always present, most of the disease happens to people who have never seen it before. Those who have survived it once are largely safe from getting sick again. The study also demonstrated that measuring the strength of the antibody grip is a powerful way to understand who is protected in a population, even when almost everyone has antibodies. This method could help health officials better understand the spread of the virus and the effectiveness of vaccines without needing to wait for years of follow-up data. The findings confirm that natural infection builds a strong defense, but they also highlight that in areas with poor sanitation, a large portion of the population remains vulnerable because they have not yet been exposed.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.